GZMB and neoplasm: Pre-clinical models have shown that the tubulin-targeting drug, paclitaxel, increases tumor cell permeability to granzyme-B (released from CTLs) (145) and upregulates major histocompatibility complex (MHC) class I expression on cancer cell lines (146) to induce tumor cell immunogenicity.